Literature DB >> 2320374

Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas.

T Ehlen1, L Dubeau.   

Abstract

The genetic events involved in human ovarian carcinoma development are still largely unknown. We have used DNA recombinant technologies to examine the genome of normal and neoplastic tissues from 12 different patients with such tumors. We used cloned DNA sequences homologous to loci showing restriction fragment length polymorphisms on chromosomal segments 3p, 5p, 6q, 11p, or 21q to determine the frequencies of losses of constitutional heterozygosity at these loci in tumor DNAs. Losses affecting loci on 3p, 6q, and 11p were found in a high percentage of the cases examined. In contrast, losses of heterozygosity were not found when we used DNA probes for the other 2 above chromosomal segments. Thus, genetic losses involving chromosomal segments 3p, 6q and 11p occurred at non-random frequencies in ovarian carcinomas, suggesting that inactivation of genes located on these chromosomes played a role in their development.

Entities:  

Mesh:

Year:  1990        PMID: 2320374

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Expression profiles of 290 ESTs mapped to chromosome 3 in human epithelial ovarian cancer cell lines using DNA expression oligonucleotide microarrays.

Authors:  Emily N Manderson; Anne-Marie Mes-Masson; Jaroslav Novak; Peter D Lee; Diane Provencher; Thomas J Hudson; Patricia N Tonin
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

2.  Identification of rapid turnover transcripts overexpressed in thyroid tumors and thyroid cancer cell lines: use of a targeted differential RNA display method to select for mRNA subsets.

Authors:  R Gonsky; J A Knauf; R Elisei; J W Wang; S Su; J A Fagin
Journal:  Nucleic Acids Res       Date:  1997-10-01       Impact factor: 16.971

3.  Linkage analysis and allelic imbalance in human breast cancer kindreds using microsatellite markers from the short arm of chromosome 3.

Authors:  J T Bergthorsson; G Eiriksdottir; R B Barkardottir; V Egilsson; A Arason; S Ingvarsson
Journal:  Hum Genet       Date:  1995-10       Impact factor: 4.132

4.  Global or Granulosa Cell-Specific Pten Mutations in Combination with Elevated FSH Levels Fail to Cause Ovarian Tumours in Mice.

Authors:  Dannielle H Upton; Kirsty A Walters; Rachel E Allavena; Mark Jimenez; Reena Desai; David J Handelsman; Charles M Allan
Journal:  Horm Cancer       Date:  2016-08-09       Impact factor: 3.869

5.  Altered chromosome 6 in immortal human fibroblasts.

Authors:  K Hubbard-Smith; P Patsalis; J R Pardinas; K K Jha; A S Henderson; H L Ozer
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

6.  Loss of heterozygosity on chromosome 6q27 and p53 mutations in epithelial ovarian cancer.

Authors:  M Suzuki; S Saito; Y Saga; M Ohwada; I Sato
Journal:  Med Oncol       Date:  1998-07       Impact factor: 3.064

7.  A common region of deletion on chromosome 17q in both sporadic and familial epithelial ovarian tumors distal to BRCA1.

Authors:  A K Godwin; L Vanderveer; D C Schultz; H T Lynch; D A Altomare; K H Buetow; M Daly; L A Getts; A Masny; N Rosenblum
Journal:  Am J Hum Genet       Date:  1994-10       Impact factor: 11.025

Review 8.  NAD(P)H:quinone oxidoreductase1 (DT-diaphorase) expression in normal and tumor tissues.

Authors:  M Belinsky; A K Jaiswal
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

9.  H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression.

Authors:  E Adriaenssens; L Dumont; S Lottin; D Bolle; A Leprêtre; A Delobelle; F Bouali; T Dugimont; J Coll; J J Curgy
Journal:  Am J Pathol       Date:  1998-11       Impact factor: 4.307

10.  Polymerase chain reaction allelotyping of human ovarian cancer.

Authors:  R J Osborne; V Leech
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.